Abstract
Glioblastoma is immunologically "cold" and resistant to single-agent immune-checkpoint inhibitors (ICI). Our previous study of neoadjuvant pembrolizumab in surgically-accessible recurrent glioblastoma identified a molecular signature of response to ICI and suggested that neoadjuvant pembrolizumab may improve survival. To increase the power of this observation, we enrolled an additional 25 patients with a primary endpoint of evaluating the cell cycle gene signature associated with neoadjuvant pembrolizumab and performed bulk-RNA seq on resected tumor tissue (NCT02852655). Neoadjuvant pembrolizumab was associated with suppression of cell cycle/cancer proliferation genes and upregulation of T-cell/interferon-related gene expression. This signature was unique to patients treated with neoadjuvant pembrolizumab and was an independent positive risk factor for survival. Our results demonstrate a clear pharmacodynamic effect of anti-PD1 therapy in glioblastoma and identify pathways that may mediate resistance. However, we did not confirm a survival benefit to neoadjuvant pembrolizumab in recurrent glioblastoma and our secondary endpoint of PFS-6 was 19.5% (95% CI: 9.29-41.2%) for the pooled neoadjuvant cohorts. Our new data suggests some patients may exhibit innate resistance to pre-surgical ICI and require other concomitant therapies to sensitize effectively.
Introduction
Glioblastoma (GBM) remains one of the most challenging malignancies to treat due to its "immunologically cold" nature, which effectively shields it from the immune system. While immune checkpoint inhibitors (ICIs) like pembrolizumab have revolutionized the treatment of cancers such as melanoma, they have largely failed to produce significant clinical benefits in GBM.
Previous pilot data suggested a potential "window-of-opportunity": administering pembrolizumab before surgery (neoadjuvant) might prime the immune system while the tumor antigens are still present in bulk. This study presents the results of a stage 2 expansion cohort designed to validate the molecular response signature of neoadjuvant treatment and investigate the mechanisms of resistance in a larger patient population.
Methods
The study utilized a stage 2 single-arm expansion cohort (NCT02852655) involving 25 patients with recurrent, surgically accessible GBM. Patients received one dose of pembrolizumab approximately 14 days before surgery, followed by adjuvant doses every three weeks post-recovery.
Molecular analysis was performed using bulk RNA-sequencing on resected tumor tissue. The researchers employed Gene Set Variation Analysis (GSVA) to score gene signatures, specifically focusing on cell cycle/proliferation (e.g., Farmer Breast Cancer Cluster 2) and immune signaling (e.g., Ayers IFN genes). Results were pooled with the original stage 1 trial data for a total of 49 patients to increase statistical power.
Results
Molecular Pharmacodynamics
The study confirmed that neoadjuvant pembrolizumab successfully modulates the tumor microenvironment at a molecular level. Neoadjuvant treatment was associated with a significant suppression of cell cycle and cancer proliferation genes (p=0.009) and an upward trend in interferon-gamma (IFN-γ) signaling (p=0.08) compared to adjuvant-only treatment.
Survival and Risk Factors
Despite the clear pharmacodynamic effect, the clinical survival benefit seen in the pilot study did not hold up in the broader expansion cohort. The median overall survival (OS) in this expansion cohort was 6.8 months (204 days), significantly lower than the 13.7 months observed in the initial pilot group. The 6-month progression-free survival (PFS-6) for the pooled neoadjuvant cohorts was 19.5%.
Analysis of the pooled data identified the cell cycle gene signature as a critical independent risk factor for survival. Multivariate analysis showed that high expression of this signature (Farmer Cluster 2) was associated with a 4.09x higher risk of death (p=0.006), indicating that the inability of the drug to shut down the tumor's proliferative machinery is a major driver of treatment failure.
Subgroup analysis further revealed that patients in "Group 3" (High IFN, Low Cell Cycle) lived nearly twice as long as those in other groups (median OS of 13.8 months). Conversely, "Group 4" patients exhibited high immune signaling but failed to suppress cell cycle genes; these tumors were enriched for STAT3 and TNF-α signaling, suggesting a state of chronic inflammation that promotes tumor growth rather than fighting it.
Discussion
The results of this stage 2 expansion cohort provide a critical reality check for neoadjuvant immunotherapy in GBM. While the treatment successfully induces desired molecular changes—suppressing proliferation and boosting immune signaling—these changes do not translate into a survival benefit for the majority of patients. The findings suggest that innate resistance and chronic inflammatory pathways may counteract the benefits of immune activation. Future trials should explore combination therapies that target these resistance mechanisms to effectively sensitize glioblastoma to immune checkpoint inhibition.
Summary updated